H.C. Wainwright Starts Traws Pharma Inc. (TRAW) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts TRAW Hot Sheet
Price: $0.37 -2.63%
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
0 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
H.C. Wainwright initiates coverage on Traws Pharma Inc. (NASDAQ: TRAW) with a Buy rating and a price target of $8.00.
For an analyst ratings summary and ratings history on Traws Pharma Inc. click here. For more ratings news on Traws Pharma Inc. click here.
Shares of Traws Pharma Inc. closed at $2.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MSG Rangers, Huron Consulting to join S&P SmallCap 600
- PreveCeutical closes first tranche of private placement at $0.03 per unit
- SpaceX in talks to access 80,000 cell sites for wireless network - Bloomberg
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
